FDA Submits Interim Peptide Compounding Policy for White House Review: What Pharmacies Should Know
Overview of the Regulatory Action According to a client alert from the law firm Buchanan Ingersoll & Rooney PC, the U.S.
Read Full StoryRecent Regulatory News
Pharmacists Must Guide Peptide Talks Pending FDA Action | NCPA 2026
Pharmacists Must Guide Peptide Talks Pending FDA Action, NCPA 2026 Session Signals Pharmacists are being urged to take a proactive role in counseling patients on peptide therapies even as the Food an...
Houston Pharmacy Behind Recalled Compounded Tirzepatide Vials Drew 14 FDA Inspection Observations, Including Exposed Skin and Research-Grade Ingredients
Houston Compounding Pharmacy Faces Scrutiny After FDA Finds 14 Violations Tied to Recalled Tirzepatide Vials A Houston-based compounding pharmacy linked to a recall of compounded tirzepatide injectab...
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
Apothecary Pharma Recalls Compounded Tirzepatide and NAD+ Vials Over Sterility Concerns Apothecary Pharma has issued a recall of compounded tirzepatide and NAD+ (nicotinamide adenine dinucleotide) in...
North Carolina Compounder Recalls Tirzepatide Vials…
North Carolina Compounder Recalls Tirzepatide Vials Amid Ongoing Scrutiny of Compounded GLP-1 Products A compounding pharmacy based in North Carolina has issued a recall of tirzepatide vials, accordi...
Twenty AGs Issue Letter on Chinese-Sourced Ingredients in Some Compounded GLP-1s and Peptides
Twenty State Attorneys General Raise Alarms Over Chinese-Sourced Ingredients in Compounded GLP-1 Drugs A coalition of twenty state attorneys general has issued a letter addressing concerns about Chin...